Mast cell involvement in the progression of peritoneal fibrosis in rats with chronic renal failure

Nephrology ◽  
2015 ◽  
Vol 20 (9) ◽  
pp. 609-616 ◽  
Author(s):  
Itsuro Kazama ◽  
Asuka Baba ◽  
Yasuhiro Endo ◽  
Hiroaki Toyama ◽  
Yutaka Ejima ◽  
...  
2019 ◽  
Vol 1 (2) ◽  
pp. 57-70
Author(s):  
Igor Lamotkin ◽  
Daniil Korabelnikov ◽  
Andrey Lamotkin

Introduction. Chronic itch is a frequent symptom of internal diseases and causes a significant decrease in the patients’ quality of life. Objectives were to study the structure of internal diseases that cause chronic itch in patients in a multidisciplinary hospital, and the features of chronic itch in these diseases; to evaluate the effectiveness of various treatment regimens for chronic itch in these diseases; to evaluate the possibility of widespread use in clinical practice of the Numeric Rating Scale for the measuring the se-verity of chronic itch in the initial diagnosis and in the determination the effectiveness of treatment. Patients and Methods. Chronic skin itching was studied in patients with various diseases undergoing inpatient treatment at the Burdenko Main Military Clinical Hospital. The study included 125 patients: 20 (16%) with chronic renal failure, 17 (13.6%) with liver diseases, 24 (19.2%) with myeloproliferative, 32 (25.6%) with lymphoproliferative and 32 (25.6%) endocrine diseases. In-dividual antipruritic therapy was selected for each patient with different systemic pathology, considering diseases that cause itching. Results. The most effective drugs in the treatment of chronic itching in patients with chronic renal failure were sorbents, gabapentin and capsaicin in the form of an ointment or cream, with cholestasis - cholestyramine, ursodeoxycholic acid, rifampicin and tacrolimus in the form of an ointment, with true polycythemia - antihistamines and mast cell inhibitors, with Hodgkin's lymphoma and mycosis fungoides - mast cell inhibitors, gabapentin and ointments with glucocorticosteroid additives, with diabetes mellitus - antihistamines, mast cell inhibitors and external therapy with calamine, menthol, capsaicin and glucocorticosteroids, with hypothyroidism - emollients. In patients with myeloproliferative and lymphoproliferative diseases and hyperthyroidism chronic itching completely disappeared only after effective treatment of the underlying disease. Conclusion. For each form of itching and for each patient individual therapy should be selected. The most effective treatment for chronic skin itching associated with systemic origin is the successful treatment of the underlying disease. The numerical rating scale is a reliable scale for measuring the severity of itching, however, it cannot consider all the complexity and features of itching.


2003 ◽  
Vol 73 (3) ◽  
pp. 215-220 ◽  
Author(s):  
de Gómez Dumm ◽  
Giammona ◽  
Touceda

Dyslipidemia and increases in plasma homocysteine usually occur at end-stage renal disease; both are recognized as risk factors for atherosclerosis. Folate administration reduces homocysteine concentration. In this study we determined the effect of a high dose of folic acid (40 mg intravenous injection three times a week) on plasma and red blood cell lipid profiles in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (baseline) and after 21, 42, and 64 days of treatment. Folic acid supplementation decreased plasma homocysteine. Plasma triglyceride levels decreased whereas polyunsaturated fatty acid values increased after 21 days; then they returned to baseline levels at the end of treatment. Total cholesterol and low-density lipoprotein (LDL) cholesterol were higher than those of the baseline during all the study, whereas high-density lipoprotein (HDL) cholesterol was reduced. In erythrocyte membranes, folic acid therapy enhanced cholesterol/phospholipid ratios and the fluorescence anisotropy of diphenyl-hexatriene. We conclude that large doses of folic acid produce a favorable effect, reducing plasma homocysteine levels and protecting patients from atherosclerosis. However, as this therapy induces significant alterations in both plasma and erythrocyte membrane lipid profiles, plasma lipid values should be controlled throughout the treatment of patients with renal failure.


Sign in / Sign up

Export Citation Format

Share Document